Ativo Capital Management LLC reduced its stake in shares of Stryker Corporation (NYSE:SYK) by 13.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,199 shares of the medical technology company’s stock after selling 2,550 shares during the period. Ativo Capital Management LLC’s holdings in Stryker Corporation were worth $2,248,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Acrospire Investment Management LLC acquired a new position in shares of Stryker Corporation during the 2nd quarter worth approximately $111,000. Motco raised its position in shares of Stryker Corporation by 50.7% during the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 278 shares during the last quarter. Bollard Group LLC raised its position in shares of Stryker Corporation by 0.4% during the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 3 shares during the last quarter. Bruderman Asset Management LLC acquired a new position in shares of Stryker Corporation during the 2nd quarter worth approximately $150,000. Finally, James Investment Research Inc. acquired a new position in shares of Stryker Corporation during the 2nd quarter worth approximately $155,000. Hedge funds and other institutional investors own 74.13% of the company’s stock.
Several research analysts recently issued reports on the company. Royal Bank Of Canada restated a “buy” rating and set a $155.00 price objective on shares of Stryker Corporation in a research report on Monday, October 2nd. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $161.00 target price on shares of Stryker Corporation in a research note on Monday, October 2nd. BidaskClub raised shares of Stryker Corporation from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Cowen and Company reaffirmed a “buy” rating and issued a $160.00 target price (up from $150.00) on shares of Stryker Corporation in a research note on Sunday, July 30th. Finally, Zacks Investment Research cut shares of Stryker Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $146.78.
In other Stryker Corporation news, insider Graham A. Mclean sold 1,124 shares of the stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total value of $164,396.24. Following the completion of the sale, the insider now owns 8,983 shares in the company, valued at approximately $1,313,853.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the sale, the insider now owns 88,207 shares of the company’s stock, valued at approximately $12,909,976.52. The disclosure for this sale can be found here. 7.40% of the stock is owned by corporate insiders.
Shares of Stryker Corporation (NYSE SYK) opened at 144.69 on Wednesday. The stock’s 50 day moving average is $142.48 and its 200 day moving average is $140.29. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $149.23. The stock has a market capitalization of $54.12 billion, a PE ratio of 32.30 and a beta of 0.80.
Stryker Corporation (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.98 billion. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.39 EPS. Analysts anticipate that Stryker Corporation will post $6.45 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be given a $0.425 dividend. The ex-dividend date is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a yield of 1.17%. Stryker Corporation’s payout ratio is 37.95%.
Stryker Corporation Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.